Home
Clinical Trials
Open Label Study Assessing Ef...

Open Label Study Assessing Effectiveness Of Amlodipine/Atorvastatin In Subjects With Hypertension and Dyslipidaemia

Last Updated: 2021-01-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1250 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-10-31

Study Completion Date

2005-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the effectiveness of amlodipine/atorvastatin therapy by assessing the percentage of subjects who reach target blood pressure (BP) and LDL-C targets as defined by their governing guidelines.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Open Label Study To Assess The Effectiveness Of Amlodipine-Atorvastatin Combination In Hypertension And Dyslipidemia.

NCT00174304

Hypertension Hyperlipidemia

COMPLETED PHASE4

Amlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol Levels

NCT00143234

Hypertension Hyperlipidemia

COMPLETED PHASE3

A Randomized Study To Evaluate Efficacy And Safety Of A Fixed Combination Therapy Of Amlodipine And Atorvastatin

NCT00530946

Hypertension Hypercholesterolemia

COMPLETED PHASE3

Comparing Amlodipine/Atorvastatin Co-Administration To Amlodipine Alone In Patients With Hypertension And Dyslipidemia

NCT00174330

Hypertension Hyperlipidemia

COMPLETED PHASE4

Atorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD

NCT00159835

Cardiovascular Diseases

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension Dyslipidemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Amlodipine/Atorvastatin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who are above target LDL-C and BP who are eligible for treatment

Exclusion Criteria

* High liver enzymes

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Calgary, Alberta, Canada

Site Status

Pfizer Investigational Site

Calgary, Alberta, Canada

Site Status

Pfizer Investigational Site

Calgary, Alberta, Canada

Site Status

Pfizer Investigational Site

Calgary, Alberta, Canada

Site Status

Pfizer Investigational Site

Calgary, Alberta, Canada

Site Status

Pfizer Investigational Site

Red Deer, Alberta, Canada

Site Status

Pfizer Investigational Site

Campbell River, British Columbia, Canada

Site Status

Pfizer Investigational Site

Chilliwack, British Columbia, Canada

Site Status

Pfizer Investigational Site

New Westminster, British Columbia, Canada

Site Status

Pfizer Investigational Site

North Vancouver, British Columbia, Canada

Site Status